Eyepoint Pharmaceuticals 在 2025 年第四季度的收益和收入均未达到预期，但其股价因交易量增加而上涨。 Eyepoint Pharmaceuticals missed earnings and revenue estimates in Q4 2025, yet its stock rose on higher trading volume.

Eyepoint制药公司报告第四季度损失每股0.85美元,损失估计数8美元,收入970 000美元,远远低于预期的333万美元。 Eyepoint Pharmaceuticals reported a fourth-quarter loss of $0.85 per share, missing estimates by $0.08, and revenue of $970,000, far below the expected $3.33 million. 该公司的负净差为337.93%,股权负回报为63.80%。 The company posted a negative net margin of 337.93% and negative return on equity of 63.80%. 尽管盈利不及预期，但该股仍上涨 0.13 美元至 11.21 美元，成交量高于平均水平。 Despite the earnings miss, the stock rose $0.13 to $11.21 on above-average volume. 分析师提供好坏参半的评级,共识是“机动买”和30.50美元的目标。 Analysts offer mixed ratings, with a consensus "Moderate Buy" and a $30.50 target. 该公司利用Durasert E技术发展视网膜病治疗,仍然是一家临床阶段生物制药公司。 The company, developing retinal disease treatments using Durasert E technology, remains a clinical-stage biopharmaceutical firm.